Potentiation of haloperidol by  -methyldopa in the treatment of schizophrenic patients.
D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000138:chemical synthesis; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004357:Drug Synergism; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008750:Methyldopa / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D011674:Pulse / Q000187:drug effects; D012156:Reticulocytes / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy*; D013997:Time Factors; D014717:Vertigo / Q000139:chemically induced
D000978:Antiparkinson Agents; D008750:Methyldopa; D006220:Haloperidol